Peptides for Weight Loss: A 2026 Guide to What Actually Works

When people search for peptides for weight loss, the medications with the strongest human trial evidence are the FDA-approved GLP-1 receptor agonists. These are peptide-based drugs given by subcutaneous injection, and the two most studied are semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP and GLP-1 receptor agonist). They are prescription-only and are used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in people who meet specific body mass index (BMI) criteria. The trial efficacy figures cited below were obtained with the FDA-approved branded products at the doses studied, and they do not establish the efficacy or safety of any compounded version. Many other compounds marketed online as “weight loss peptides” are not FDA-approved and lack robust human evidence. This guide explains what these peptides actually are, how they work, what the trials show, and what their regulatory status looks like in 2026. None of this is medical advice, individual results vary, and you should talk to a licensed provider before starting any therapy.

What are peptides, and which ones are used for weight loss?

Peptides are short chains of amino acids. Some peptides function as signaling molecules in the body, and certain peptide-based medications have been developed and approved as drugs. In the context of weight management, the peptide medications that have been rigorously studied in human trials and approved by the FDA are GLP-1 receptor agonists. Semaglutide and tirzepatide are peptides administered by subcutaneous injection.

It is worth being precise here, because the term “peptides for weight loss” is used loosely in marketing. The medications with real, trial-level human evidence are the branded GLP-1 and GIP/GLP-1 products studied at specific doses. Other so-called “research peptides” and amino-acid injections that get grouped under the same heading are a different category entirely, and we address them honestly further down.

How do GLP-1 peptides work for weight loss?

GLP-1 (glucagon-like peptide-1) is an incretin hormone. GLP-1 receptor agonists mimic its activity. Tirzepatide goes a step further as a dual agonist, activating both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. By activating these incretin hormone receptors, these medications are understood to reduce food intake and slow gastric emptying.

In practical terms, the proposed mechanisms include slowing how quickly the stomach empties, increasing the sense of fullness (satiety), and reducing appetite. The result for many patients in clinical trials was reduced caloric intake over time. These are population-level findings, individual responses vary, and the medications are studied and labeled as an adjunct to diet and physical activity, not as a standalone fix.

Semaglutide: the first once-weekly GLP-1 for weight management

Semaglutide is marketed as Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management). Wegovy (semaglutide 2.4 mg) was FDA-approved for chronic weight management on June 4, 2021, as the first once-weekly GLP-1 therapy for weight management.

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. In adults, the criteria are obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related comorbidity. The indication also extends to adolescents 12 and older with obesity. It is not a standalone or cosmetic drug.

In the STEP-1 trial, adults taking semaglutide 2.4 mg lost an average of about 14.9% of body weight at 68 weeks, compared with about 2.4% with placebo (commonly summarized as roughly 15%). That figure is an average trial outcome across a study population for the branded product at the studied dose, not a promise of results for any individual.

Tirzepatide: a dual GIP and GLP-1 receptor agonist

Tirzepatide is marketed as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). Zepbound was FDA-approved for chronic weight management on November 8, 2023, as the first dual GIP and GLP-1 receptor agonist approved for weight management.

As a dual agonist, tirzepatide activates both incretin hormone receptors to reduce food intake and slow gastric emptying. In the SURMOUNT-1 trial, mean weight reduction at week 72 in adults with obesity or overweight without diabetes was about 15.0% at the 5 mg dose, about 19.5% at 10 mg, and about 20.9% at 15 mg, compared with about 3.1% with placebo. These are average outcomes from a controlled trial using the branded product at the studied doses, not guaranteed results for any individual.

Tirzepatide versus semaglutide: what the head-to-head trial showed

For a long time, comparisons between these two medications relied on numbers drawn from separate trials, which is not a rigorous way to compare drugs. That changed with SURMOUNT-5, the first direct head-to-head comparison, published in the New England Journal of Medicine on May 11, 2025. In that trial, mean weight change at 72 weeks was -20.2% with tirzepatide versus -13.7% with semaglutide, which the authors describe as roughly a 47% greater relative reduction. Because it is a direct comparison, SURMOUNT-5 is more informative than comparing across separate studies, though it was an open-label trial, which is a limitation to keep in mind. As with all trial data, these were obtained with the branded products at studied doses, these are population averages, and individual results vary.

Comparison table: the main evidence-backed options

Option	What it is	FDA status for weight management	Average trial weight change
Semaglutide (Wegovy 2.4 mg)	GLP-1 receptor agonist peptide, weekly subcutaneous injection	FDA-approved June 4, 2021 (branded product)	~14.9% at 68 weeks (STEP-1) vs ~2.4% placebo
Tirzepatide (Zepbound)	Dual GIP and GLP-1 receptor agonist peptide, weekly subcutaneous injection	FDA-approved November 8, 2023 (branded product)	~15.0% to ~20.9% at 72 weeks (SURMOUNT-1) vs ~3.1% placebo; -20.2% vs semaglutide -13.7% (SURMOUNT-5)
Compounded semaglutide/tirzepatide	Pharmacy-prepared versions of the same molecules	NOT FDA-approved; not reviewed for safety, effectiveness, or quality	No FDA-reviewed trial data; branded-trial figures do not transfer to compounded versions
“Research peptides” (e.g., AOD-9604)	Investigational compounds marketed online	NOT FDA-approved for weight loss or any medical use	Weak, inconsistent evidence; obesity program discontinued
Lipotropic/MIC + B12 injections	Amino acids (methionine, inositol, choline) plus a vitamin, not peptides	NOT FDA-approved for weight loss; no single approved product	Limited published evidence; adjunct use only

FDA status: branded products versus compounded versions

This distinction matters a great deal, and it has changed significantly. The branded products listed above, Wegovy and Zepbound, are FDA-approved for chronic weight management. Compounded semaglutide and tirzepatide are a different thing. Compounded GLP-1s are not FDA-approved, and they are not reviewed by the FDA for safety, effectiveness, or quality. The FDA has logged hundreds of adverse-event reports tied to compounded versions, with figures of 455 or more for compounded semaglutide and 320 or more for compounded tirzepatide as of early 2025, many involving dosing errors from multi-dose vials. Because compounded versions have not been evaluated by the FDA, the trial efficacy figures from the branded products do not establish the efficacy or safety of any compounded preparation.

The 2026 compounding landscape

During the recent national shortages, pharmacies were permitted, under specific conditions, to compound these medications. Those shortages are over. The FDA determined that the tirzepatide shortage resolved on December 19, 2024, and the semaglutide injection shortage resolved on February 21, 2025.

Once the shortages resolved, FDA enforcement-discretion deadlines required compounders to stop mass-compounding these drugs in early-to-mid 2025. State-licensed 503A pharmacies had to stop compounding tirzepatide essentially immediately (with a court-contested grace window around February to March 2025) and semaglutide by about April 22, 2025. The 503B outsourcing facilities had to stop tirzepatide by March 19, 2025, and semaglutide by about May 22, 2025. The Outsourcing Facilities Association sued; courts denied the preliminary injunction requests in both cases, and the deadlines held.

On April 30, 2026, the FDA went further and proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, based on an affirmative finding of “no clinical need” for outsourcing facilities to compound them from bulk drug substance. According to the FDA’s April 30, 2026 announcement, “When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.” The public comment period runs through about June 29, 2026. The proposal is not yet final, but it signals FDA intent to permanently block large-scale bulk compounding even if a future shortage recurs.

The practical takeaway: large-scale or mass compounding of semaglutide and tirzepatide is no longer permitted now that the drugs are off shortage. As a general matter, narrow patient-specific 503A compounding may still occur only in limited circumstances, such as a documented clinical need like an allergy to an inactive ingredient or a dose or form that is not commercially available. It is not a routine “cheaper alternative” weight-loss supply, and compounded versions remain not FDA-approved and not reviewed by the FDA for safety, effectiveness, or quality. Whether any specific compounded prescription is appropriate and lawful for a given patient is a clinical and regulatory determination that a licensed provider and pharmacy must make on an individual basis.

A cautious word on “research peptides”

Search results and supplement marketing frequently surface compounds like AOD-9604, tesofensine, and various peptide fragments as “weight loss peptides.” We do not promote these, and the evidence does not support presenting them as proven or available treatments.

AOD-9604 is not FDA-approved for weight loss or any medical use. It is an investigational or research peptide; its obesity development program was discontinued after it failed to produce significant weight loss in a 24-week trial of 536 subjects around 2007. The evidence for weight loss is weak and inconsistent.

Tesofensine is not FDA-approved for obesity. It is an investigational drug, a monoamine reuptake inhibitor rather than a GLP-1 peptide, that has completed Phase 2 and Phase 3 work; as of late 2024 it was still not yet approved even in Mexico. It should not be presented as an available or proven weight-loss treatment in the United States.

What about lipotropic / MIC + B12 injections?

These are commonly bundled with weight-loss marketing, but they are not peptides. Lipotropic or MIC injections combine methionine, inositol, and choline, which are amino acids and a related nutrient, often paired with vitamin B12. They are not FDA-approved for weight loss, there is no single FDA-approved MIC product, and formulations are compounded and vary. Published evidence for a weight-loss benefit is limited. They are not a primary weight-loss therapy and are used only as physician-supervised adjuncts alongside diet and exercise, and they should not be relied upon as a weight-loss treatment.

Safety: what every candidate should know

GLP-1 and GIP/GLP-1 medications are prescription-only and require medical screening and supervision. The most common adverse effects in this class are predominantly gastrointestinal, including nausea, vomiting, diarrhea, and constipation. The product labels carry a boxed warning for the risk of thyroid C-cell tumors, based on rodent data, and contraindications for patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Because of these issues, this therapy is not appropriate for everyone and must be evaluated by a clinician. This information is not a substitute for a provider’s evaluation, and no one should self-dose these medications.

Who is a candidate, and how do you start?

The approved indication offers a useful starting framework. The branded GLP-1 medications are indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related comorbidity, and the indication also extends to adolescents 12 and older with obesity. Whether any individual is an appropriate candidate is a clinical decision that accounts for medical history, the contraindications noted above, and other factors a licensed provider will review.

A reasonable way to start is a consultation with a licensed provider who can confirm eligibility, screen for contraindications, discuss realistic expectations based on trial averages rather than promises, and determine whether a prescription therapy is appropriate. You can see how the provider-led process works on our how it works page.

How Revive approaches this

Revive Longevity is provider-centered. Any GLP-1 or GIP/GLP-1 therapy is prescription-only and supervised, with eligibility, screening, and dosing handled by a licensed provider rather than left to self-direction. We want to be clear and specific about what we offer. Where Revive dispenses tirzepatide, it is a compounded preparation prepared by a state-licensed pharmacy, not the branded FDA-approved product (Zepbound or Mounjaro). Any such compounded preparation is dispensed only where a licensed provider and pharmacy document an individual, patient-specific clinical need consistent with the 503A limits described above; it is not offered as a routine or cheaper alternative to the FDA-approved branded products. Compounded tirzepatide is not FDA-approved and is not reviewed by the FDA for safety, effectiveness, or quality, and the branded-product trial results described above do not establish the efficacy or safety of a compounded version. We do not promote unproven “research peptides,” and we do not present lipotropic or MIC and B12 injections as a primary weight-loss therapy.

The regulatory landscape described above has materially narrowed when GLP-1 compounding is permitted, and whether any compounded prescription is appropriate and lawful for a given patient is a determination a licensed provider and pharmacy make individually. If you are exploring evidence-backed options, the best next step is to talk with a licensed provider about whether you are a candidate. Please keep these disclosures in mind: individual results vary, the trial figures above are population averages from the branded products and not promises, all therapy in this class is prescription-only with eligibility determined by a licensed provider, and where a product is compounded rather than branded it is not FDA-approved and not reviewed by the FDA for safety, effectiveness, or quality. To understand the provider-led evaluation, screening, and prescribing process, including the eligibility and compounding disclosures, read our how it works page.

Frequently asked questions

Are peptides for weight loss the same as GLP-1 medications?

The peptides with the strongest human trial evidence for weight management are GLP-1 receptor agonists, specifically semaglutide and the dual GIP/GLP-1 agonist tirzepatide. These are peptide-based prescription medications given by subcutaneous injection. Many other compounds marketed as “weight loss peptides” online are not FDA-approved and lack robust human evidence.

Is compounded semaglutide or tirzepatide FDA-approved?

No. Compounded semaglutide and tirzepatide are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. The FDA has logged hundreds of adverse-event reports tied to compounded versions. With the shortages resolved, large-scale or mass compounding is no longer permitted, and only narrow patient-specific 503A compounding for a documented clinical need may remain, as determined by a licensed provider and pharmacy.

How much weight did people lose in the clinical trials?

These are average trial outcomes from the branded products at studied doses, not promises, and they do not apply to compounded versions. In STEP-1, adults on semaglutide 2.4 mg lost an average of about 14.9% of body weight at 68 weeks versus about 2.4% with placebo. In SURMOUNT-1, tirzepatide produced mean reductions of roughly 15.0% to 20.9% at 72 weeks versus about 3.1% with placebo. In the head-to-head SURMOUNT-5 trial, mean weight change was -20.2% with tirzepatide versus -13.7% with semaglutide. Individual results vary.

Are “research peptides” like AOD-9604 or tesofensine safe and effective for weight loss?

They are not FDA-approved for weight loss, and we do not promote them. AOD-9604 is an investigational peptide whose obesity development program was discontinued after it failed to produce significant weight loss in a 24-week trial. Tesofensine is an investigational drug (a monoamine reuptake inhibitor, not a GLP-1 peptide) that is not FDA-approved for obesity. Neither should be presented as a proven or available weight-loss treatment in the United States.

Are lipotropic or MIC + B12 injections peptides that cause weight loss?

No. Lipotropic or MIC injections combine methionine, inositol, and choline (amino acids and a related nutrient), often with vitamin B12. They are not peptides and are not FDA-approved for weight loss. Published evidence for a weight-loss benefit is limited, and they are used only as physician-supervised adjuncts alongside diet and exercise, not as a primary weight-loss therapy.

What are the main side effects and contraindications of GLP-1 medications?

The most common adverse effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation. The labels carry a boxed warning for the risk of thyroid C-cell tumors based on rodent data, with contraindications for patients who have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). These medications are prescription-only and require medical screening and supervision; talk to a licensed provider.